ASCO26: Alicia Morgans, MD, MPH, ARACOG - Top-Institutions - MDSpire

ASCO26: Alicia Morgans, MD, MPH, ARACOG

Dr. Alicia Morgans of Dana-Farber Cancer Institute reported at #ASCO26 that ARACOG found darolutamide was associated with less decline in cognitive testing than enzalutamide, which may help guide treatment choice.

  • July 1, 2026

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Oncology

  • #2

    ARACOG
    ARACOG

    Unknown, Unknown

    Key Differentiators

    • Oncology

  • #3

    The University of Chicago Medicine
    The University of Chicago Medicine

    Chicago, IL

    Key Differentiators

    • Oncology

Original Source(s)

ASCO26: Alicia Morgans, MD, MPH, ARACOG

  • July 1, 2026

Related Content

Clinicopathological and molecular characteristics of primary pulmonary choriocarcinoma: a case report and systematic review

Usefulness of indigo carmine chromoendoscopy for detecting gastric cancer and gastric adenoma during upper gastrointestinal endoscopy (INDIGO study): protocol for a prospective multicentre observational study

From voice biomarkers to telemedicine screening: developing and evaluating a voice-based AI model for laryngeal lesion detection using the Bridge2AI-Voice dataset